The National Medical Products Administration (NMPA) has granted marketing approval for Hui Sheng Bio-pharmaceutical Co., Ltd’s Category 1 drug janagliflozin, which is indicated for the control of blood sugar levels in adults with type 2 diabetes. The drug can be used as a monotherapy or in combination with metformin.
Janagliflozin, a sodium glucose co transporter 2 (SGLT-2) inhibitor, offers protective benefits for the cardiovascular system and kidneys in addition to effectively managing blood sugar levels. The drug is protected by patents in several major markets, including mainland China, the US, Europe, Japan, South Korea, and Hong Kong. Janagliflozin distinguishes itself from traditional hypoglycemic agents with its enduring efficacy, lower risk of hypoglycemia, and potential weight loss benefits for patients with diabetes, coupled with a favorable safety profile.- Flcube.com
